Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2015-05-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
独立董事关于2015年股权激励计划所涉限制性股票授予的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the 2015 equity incentive plan involving restricted stock grants. It discusses compliance with relevant laws, the number of shares granted, and the eligibility of the incentive recipients. This is a formal opinion related to a share-based compensation plan rather than a financial report, earnings release, or management discussion. It is not an announcement of voting results or a proxy solicitation. The content fits best under Regulatory Filings (RNS) as it is a regulatory compliance document related to equity incentive plans and does not fit other more specific categories.
2015-05-20 Chinese
北京德恒（昆明）律师事务所关于公司2015年股权激励计划所涉限制性股票授予相关事宜的法律意见书（二）
Board/Management Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the implementation of a 2015 equity incentive plan involving restricted stock grants by Kunming Pharmaceutical Group Co., Ltd. It references relevant Chinese laws and regulations, the company's board meetings, shareholder meetings, and compliance with regulatory requirements for the equity incentive plan. The document is a detailed legal opinion on the legitimacy and compliance of the equity incentive plan and the restricted stock grants, rather than a financial report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. The content focuses on legal and regulatory compliance related to equity incentive plans, which aligns with governance and management information about the company’s internal decisions and approvals. Therefore, the most appropriate classification is Board/Management Information (MANG).
2015-05-20 Chinese
关于召开2015年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2015 second extraordinary general meeting of shareholders (临时股东大会) for Kunming Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data, earnings, or management discussion. It is an announcement informing shareholders about the meeting and how to participate, not the actual meeting minutes or voting results. The document length is short (2531 characters) and it serves as a meeting notice. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2015-05-20 Chinese
2015年限制性股票激励计划激励对象名单
Director's Dealing Classification · 95% confidence The document lists the names, positions, and quantities of restricted stock granted to specific executives of the company. It details the allocation of restricted stock under a 2015 stock incentive plan. This is a report of personal share transactions or share-based compensation for directors and senior management. It is not a full financial report, earnings release, or general announcement. The content fits the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). The document length is short but contains specific data on share grants to directors, confirming it is not merely an announcement but a disclosure of insider share dealings.
2015-05-20 Chinese
北京德恒（昆明）律师事务所关于公司2015年股权激励计划所涉限制性股票授予相关事宜的法律意见书（三）
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the implementation of a 2015 equity incentive plan involving restricted stock grants by Kunming Pharmaceutical Group Co., Ltd. It references relevant Chinese laws and regulations, the company's board meetings, shareholder meetings, and compliance with regulatory requirements for the equity incentive plan. The document is a detailed legal opinion on the legitimacy and compliance of the equity incentive plan and the restricted stock grants, rather than a financial report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. The content is focused on legal and regulatory compliance related to equity incentive plans, which aligns with the category of Regulatory Filings (RNS) as it is a compliance/legal document that does not fit into other specific categories like Annual Report, Earnings Release, or Capital/Financing Update.
2015-05-20 Chinese
天然植物原料药创新基地建设项目可行性研究报告
Regulatory Filings Classification · 90% confidence The document is titled as a "Feasibility Study Report" for a construction project of a natural plant raw material drug innovation base by Kunming Pharmaceutical Group Co., Ltd. It contains detailed sections on project background, market analysis, construction plans, environmental protection, safety, investment estimation, financial analysis, and risk assessment. The content is focused on the feasibility and planning of a specific project rather than financial performance, regulatory compliance, or shareholder information. It is not an annual report, audit report, earnings release, or any other financial or regulatory filing. It is a comprehensive feasibility study report, which does not match any of the specific financial or regulatory filing categories provided. Therefore, the best fit is the fallback category Regulatory Filings (RNS) as it does not neatly fit into other categories.
2015-05-20 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.